Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18362410 | IMMUNOMODULATORY PROTEINS AND RELATED METHODS | Non-Final OA | Flagship Pioneering Innovations VII, LLC |
| 18347362 | COMBINATION THERAPY EMPLOYING A PD1-LAG3 BISPECIFIC ANTIBODY AND A CD20 T CELL BISPECIFIC ANTIBODY | Non-Final OA | Hoffmann-La Roche Inc. |
| 18340608 | ANTI-HUMAN CYSTINOSIN ANTIBODIES AND METHODS OF USE THEREOF | Non-Final OA | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM |
| 18353183 | Synergistic Inhibition of eIF5A and Notch Signaling | Non-Final OA | The University of Toledo |
| 18452405 | EGFR TARGETING PEPTIDE CONJUGATE | Non-Final OA | Chapman University |
| 18263439 | NOVEL CHIMERIC ANTIGEN RECEPTOR AND USE THEREOF | Non-Final OA | BIOHENG THERAPEUTICS LIMITED |
| 18262930 | BISPECIFIC CS1-BCMA CAR-T CELL AND APPLICATION THEREOF | Non-Final OA | WUHAN SIAN BIOTECHNOLOGY CO., LTD |
| 18274152 | Genetically Modified Hepatocyte Populations | Non-Final OA | Cytotheryx, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy